United States Retinal Drugs Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032

1.  Report Overview

1.1.  Report Description

1.2.  Research Methods

1.3.  Research Approaches

2.  Executive Summary

3.  Market Overview

3.1.  Introduction

3.2.  Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

3.2.4.  Challenges

3.3.  PEST-Analysis

3.4.  Porter's Diamond Model for the United States Retinal Drugs Market

3.5.  IGR-Growth Matrix Analysis

3.6.  Value Chain Analysis of the United States Retinal Drugs Market

3.7.  Competitive Landscape in the United States Retinal Drugs Market

4.  The United States Retinal Drugs Market by Drug Class

4.1.  Anti-VEGF Agents

4.2.  Corticosteroids

4.3.  Photodynamic Therapy Agents

4.4.  Antioxidants

4.5.  Retinal Cell Proliferation Inhibitors

5.  The United States Retinal Drugs Market by Disease Category

5.1.  Age-related Macular Degeneration (AMD)

5.2.  Diabetic Retinopathy

5.3.  Retinal Vein Occlusion

5.4.  Uveitis

5.5.  Inherited Retinal Degenerations

6.  The United States Retinal Drugs Market by Route of Administration

6.1.  Intravitreal Injections

6.2.  Sub-tenon Injections

6.3.  Topical Drops

6.4.  Oral Administration

6.5.  Transscleral Drug Delivery Systems

7.  The United States Retinal Drugs Market by End User

7.1.  Hospitals

7.2.  Ophthalmology Clinics

7.3.  Ambulatory Surgical Centers

7.4.  Research Institutes

7.5.  Home Care Settings

8.  Company Profiles

8.1.  Company 1

8.2.  Company 2

8.3.  Company 3

8.4.  Company 4

8.5.  Company 5